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OX3 7BN, UKTransforming growth factor beta (TGF-b) is crucial for regu-
lation of the endothelial cell (EC) homeostasis. Perturbation
of TGF-b signaling leads to pathological conditions in
the vasculature, causing cardiovascular disease and fibrotic
disorders. The TGF-b pathway is critical in endothelial-to-
mesenchymal transition (EndMT), but a gap remains in our
understanding of the regulation of TGF-b and related
signaling in the endothelium. This study applied a gain-
and loss-of function approach and an in vivo model of skin
wound healing to demonstrate that miR-148b regulates
TGF-b signaling and has a key role in EndMT, targeting
TGFB2 and SMAD2. Overexpression of miR-148b increased
EC migration, proliferation, and angiogenesis, whereas its in-
hibition promoted EndMT. Cytokine challenge decreased
miR-148b levels in ECs while promoting EndMT through
the regulation of SMAD2. Finally, in a mouse model of skin
wound healing, delivery of miR-148b mimics promoted
wound vascularization and accelerated closure. In contrast,
inhibition of miR-148b enhanced EndMT in wounds, result-
ing in impaired wound closure that was reversed by SMAD2
silencing. Together, these results demonstrate for the first
time that miR-148b is a key factor controlling EndMT and
vascularization. This opens new avenues for therapeutic appli-
cation of miR-148b in vascular and tissue repair.Received 22 September 2017; accepted 4 May 2018;
https://doi.org/10.1016/j.ymthe.2018.05.002.
Correspondence: Andrea Caporali, PhD, University/British Heart Foundation
Centre for Cardiovascular Science, The Queen’s Medical Research Institute, Uni-
versity of Edinburgh, Edinburgh EH16 4TJ, UK.
E-mail: a.caporali@ed.ac.ukINTRODUCTION
It is well known that the transforming growth factor beta (TGF-b)
signaling pathway plays a crucial role in the regulation of vascular
function in health and disease.1 During canonical activation of the
TGF-b pathway, TGF-b binds to the heteromeric receptor complex
formed by the activin-like kinase 5 (ALK5, also known as the
TGF-b type I receptor, TGFBR1) and the TGF-b type II receptor
(TGFBR2). Phosphorylation of ALK5 by TGFBR2 kinase activates
its catalytic kinase domain allowing the activation of the receptor-
regulated Smads (i.e., SMAD2 and SMAD3), which translocate to
the nucleus, where they regulate the transcription of specific target
genes.2M
This is an open access article undeActivation of the TGF-b pathway in endothelial cells (ECs) during
angiogenesis is reported to have pro-angiogenic, as well as anti-angio-
genic effects. Discrepancies might be explained by the variations in
ligand concentration, culture conditions, cell type, and developmental
or disease stage in vivo. In addition, the effects of TGF-b signaling
depend on the interplay between different members of the TGF-b
family.3 Accumulating evidence over the past few years is revealing
the role of the TGF-b pathway in regulation of cellular plasticity,
thus including the control of EC phenotype.4 EC plasticity is repre-
sented by the endothelial-to-mesenchymal transition (EndMT), al-
lowing the endothelium to not only alter its fate but to provide a
potentially important additional source of mesenchymal cells for
participation in fibrosis.5,6 During the EndMT process, ECs lose their
endothelial specification and acquire a mesenchymal-like phenotype.
Specifically, loss of vascular endothelial cadherin (VE-cadherin) and
platelet-EC adhesion molecule 1 (PECAM-1, CD31) are observed
along with elevated expression of a-smooth muscle actin (a-SMA),
vimentin (VIM), N-cadherin, and extracellular matrix (ECM) pro-
teins like collagen type I and III.7 ECs undergoing EndMT also exhibit
cytoskeletal rearrangement, resulting in a change in cell polarity
whereby they acquire a stretched and more fibroblast-like
morphology.7 Recently, EndMT has been reported to play an impor-
tant role during the embryonic stages of cardiac and pulmonary ar-
tery development.8,9 In addition, EndMT has a pathological role
through promoting tumor growth and progression,10 contributing
to cardiac11 and renal fibrosis12 as well as vascular remodelling13
and atherosclerosis.14
MicroRNAs (miRNAs) are post-transcriptional inhibitory regulators
of gene expression that bind to complementary mRNA transcripts.15
Their capacity to simultaneously inhibit many different mRNAsolecular Therapy Vol. 26 No 8 August 2018 ª 2018 The Author(s). 1
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. TGFB2 and SMAD2 Are miR-148b Target
Genes
(A) In silico analysis of TGFB2 and SMAD2 30 UTR with
TargetScan identifies putative miR-148b-binding sites
(blue). (B) Luciferase activity at 48 hr post-co-trans-
fection of HEK293T cells with both miR-148b and the
following plasmids: 30 UTR-TGFB2, 30 UTR-SMAD2, and
pMIR as empty plasmid (n = 5). (C) Relative gene
expression of TGFB2 and SMAD2 after miR-148b
overexpression (n = 3). (D) Western blot analysis of
TGFB2 and SMAD2 in samples transfected with miR-
148b mimic versus control; b-actin is used as a loading
control (n = 3); HUVECs were transfected with miR-148b
mimic or control oligonucleotides for 48 hr. (E) EC pro-
liferation was analyzed by BrdU incorporation assay
(n = 5). (F) EC migration reported as migration speed
(mm/hr) (n = 5). (G) Representative Matrigel assay images
and quantification as total tubule length (n = 5); values
are means ± SEM. *p < 0.05; **p < 0.01 versus control
and pMIR vector in experiment b. Unpaired two-tailed
Student’s t test was applied.
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studies have revealed important roles for miRNAs as therapeutic tools
in regulating physiological and pathological angiogenesis, through
the regulation of EC function (reviewed in Caporali and
Emanueli17,18).
Several miRNAs have been identified that target elements of the TGF-
b/Smad signaling axis19 and, more recently, contribute to the EndMT
process.20 Although the role of TGF-b signaling in the regulation and
maintenance of adult EC homeostasis and plasticity is now well estab-
lished,2 less is known about the mechanisms that regulate the TGF-b
signaling pathway. Using miRNA target-prediction analysis, we have
found that miR-148b targets are strongly enriched for the compo-
nents of TGF-b pathway. The present study aims to investigate
how this miRNA regulates EC function and how it impacts on2 Molecular Therapy Vol. 26 No 8 August 2018TGF-b signaling in these cells. miR-148b,
together with miR-148a and miR-152, com-
prises the miR-148/152 family.21 Although
aberrant expression of the miR-148/152 family
has been observed in tumors, and in non-tumor
diseases such as immunoglobulin A (IgA) ne-
phropathy22 and atherosclerotic lesions;23 its
function has not been explored in ECs.
Here, we establish that in ECs, miR-148b plays a
critical role in promoting angiogenesis and
that its inhibition promotes EndMT process
through regulation of the target genes, TGFB2
and SMAD2. Furthermore, we demonstrate, in
an in vivomodel of wound healing, that overex-
pression of miR-148b increases vascularization
and accelerates wound closure, whereas miR-148b inhibition leads to an enhanced EndMT in the wound, resulting
in impaired closure.
RESULTS
miR-148b Targets TGFB2 and SMAD2 and Regulates EC
Functions
Gene set enriched analysis (miRpath24) has identified components of
the TGF-b pathway as putative targets of miR-148b (Figure S1A).
Moreover, the TargetScan algorithm25 predicted TGFB2 and
SMAD2 to be direct targets of miR-148b (Figure 1A). Accordingly,
both gene targets were predicted to contain a single conserved bind-
ing sequence for miR-148b in their 30 UTR (Figure 1A). To investigate
whether miR-148b directly binds the 30 UTR of TGFB2 and SMAD2,
we performed a luciferase reporter assay in which luciferase reporter
gene was fused to the wild-type 30 UTR of TGFB2 or SMAD2,
Figure 2. miR-148b Regulates Angiogenesis and
Accelerates Wound Healing
(A) Expression of miR-148b at 3 and 7 days after
wounding, relative to unwounded skin (n = 5). (B) Left,
representative images of control and miR-148b mimic-
treated wounds at 0 and 7 days post-wound-injury; scale
bar, 5 mm. Right, the level of wound closure is expressed
as a percentage of initial wound area (n = 8). (C) Repre-
sentative color laser Doppler images are taken at 5 days
post-wounding. The chart shows the level of wound
perfusion in mice (calculated as the ratio between treated
and control blood flow; n = 8 per group). (D) Left, immu-
nohistochemistry for CD31 and a-SMA in miR-148b
mimic-treated or control-oligonucleotide-treated skin
wounds; scale bars, 100 mm (magnification 400). Right,
quantification of vessel density expressed as CD31-
positive vessels/mm2 (n = 8). Values are means ± SEM.
*p < 0.05; **p < 0.01 versus control. Unpaired two-tailed
Student’s t test was applied.
www.moleculartherapy.org
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ity for each of the putative target genes, whereas mutation of the bind-
ing sites restored it (Figures 1B and S1B). In addition, miR-148b
mimics, at the dose of 25 nM, reduced both target gene mRNA (Fig-
ures 1C, S1C, and S1D) and protein levels (Figure 1D). Notably, miR-
148b upregulation did not affect the expression of ACVR1 and
ROCK1, previously identified target genes of miR-148/152 cluster26,27
(Figure S1E). We then investigated the role of miR-148b on the func-
tional properties of ECs. miR-148b overexpression significantly
increased the proliferation of human umbilical vein EC (HUVECs),
as demonstrated by bromodeoxyuridine (BrdU) incorporation (Fig-
ure 1E). The migration capacity of HUVECs transfected with a
miR-148b mimic was also significantly elevated (Figure 1F), along
with their ability to form tubes in an in vitro Matrigel assay
(Figure 1G).
miR-148b Promotes Angiogenesis and Accelerates Skin Wound
Healing
To follow up the in vitro results, we asked whether miR-148b could
influence angiogenesis in a mouse model of wound healing. In this
model, following skin puncture, the peak of neovascularization occurs
between days 4 and 8 after wounding. Vessel density generally returns
to initial levels around 3 weeks later. Thus, before, and at the peak of
vascularization, this model characterizes the angiogenic response.28MThree days after wound injury, the expression
of miR-148b was found to be downregulated,
going back to basal level after 7 days (Fig-
ure 2A). The analysis of Cy3-labeled miR-
148b mimics in the wounds demonstrated
that the mimics could reach the endothelium
in vivo (Figure S2A).
Topical delivery of miR-148b mimics starting
at day 3 after wounding increased the expres-sion of miR-148b and decreased the expression levels of both targets
at day 7 after wounding (Figure S2B). Moreover, miR-148b overex-
pression also accelerated wound closure (Figure 2B) and led to a sig-
nificant increase in wound perfusion detected by Doppler analysis
(Figure 2C) and vessel density (Figure 2D). These data indicate that
treatment with miR-148b mimics promotes angiogenesis and acceler-
ates wound healing in vivo.
Loss of Function of miR-148b Promotes Endothelial-
Mesenchymal Transition
To analyze the phenotypic effect of miR-148b loss-of-function on
ECs, HUVECs were transfected with anti-miR-148b oligonucleotides
(Figure S1F). The inhibition of miR-148b expression decreased the
proliferation of HUVECs (Figure 3A); however, it did not cause a
change in EC migration or tubulogenesis (Figures 3B and 3C).
Next, we examined the capacitance of the EC membrane, changes
in which reflect structural changes in the plasma membrane and re-
arrangement of the cytoskeleton (the capacitance of ECs is
1.1 mF/cm2, whereas for mesenchymal cells, it is 3.0 mF/cm2).29
Knockdown of miR-148b in ECs increased the membrane capaci-
tance, consistent with the occurrence of transition from an endothe-
lial-to-mesenchymal phenotype (Figure 3D). In line with this,
miR-148b loss-of-function increased the expression of its target
genes, TGFB2 and SMAD2 and the expression of collagen 1A1olecular Therapy Vol. 26 No 8 August 2018 3
Figure 3. Inhibition of miR-148b Induces EndMT
HUVECs were transfected with anti-miR-148b or control
oligonucleotides for 48 hr. (A) EC proliferation was
analyzed by BrdU incorporation assay (n = 5). (B) EC
migration reported as migration speed (mm/hr) (n = 5). (C)
Matrigel assay quantification as total tubules length
(n = 5). (D) Quantification of cell membrane capacitance in
HUVEC knockdown for miR-148b or control (n = 5). (E)
Relative gene expression of TGFB2, SMAD2, CD31,
VE-cadherin COL1A1, SNAIL, SLUG, TWIST, ZEB1/2,
VIM, FSP-1, and a-SMA (n = 3). (F) Western blot analysis
of TGFB2, SMAD2, p-SMAD2, SLUG, CD31, VE-cad-
herin, COL1A1, and FSP-1; b-actin is used as a loading
control (n = 3). (G) Immunofluorescence images showing
localization of CD31, VE-cadherin, COL1A1, and FSP-1
in anti-miR-148b- or control-transfected cells (n = 3);
scale bars, 50 mm (magnification 400). Values are
means ± SEM. *p < 0.05; **p < 0.01 versus control. Un-
paired two-tailed Student’s t test was applied.
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expression of CD31 and VE-Cadherin, without detectable changes in
a-SMA or VIM levels (Figure 3E). Moreover, expression analysis of
the transcription factors involved in EndMT, such as SNAIL, SLUG,
TWIST, and ZEB1/2, showed strong upregulation of SLUG after
miR-148b inhibition (Figure 3E). Western blot analysis confirmed
the upregulation of TGFB2, SMAD2 and its phosphorylation, the
appearance of mesenchymal marker COL1A1, FSP-1, along with sup-
pression of CD31 and endothelial VE-cadherin and the upregulation
of SLUG in ECs lacking miR-148b (Figure 3F). Furthermore, immu-4 Molecular Therapy Vol. 26 No 8 August 2018nofluorescence staining revealed that control-
treated HUVECs display a typically rounded/
cobblestone morphology that was lost in anti-
miR-148b-treated cells. Anti-miR-148b treat-
ment also resulted in a pronounced decrease
in CD31 and VE-cadherin and increase in
COL1A1 and FSP-1 immunoreactivity (Fig-
ure 3G). Taken together, these data show that
loss of miR-148b function leads to EndMT.
Pro-inflammatory Cytokines Promote
EndMT via Downregulation of miR-148b
It has been reported that EndMT is closely
linked to inflammation and high levels of
pro-inflammatory cytokines.30 To investigate
whether cytokine treatment could reduce the
expression of miR-148b, thus triggering
EndMT, we treated HUVECs with TNF-a,
interleukin-1b (IL-1b), TGF-b1, or TGF-b2, as
well as with a combination of cytokines for
6 days (Figures S3A–S3D). Interestingly, we
found that only the combination of TNF-a-
and IL-1b-inhibited miR-148b expression after3 days, with its strongest downregulation at 6 days (Figure 4A).
This was accompanied by significantly increased expression of
TGFB2 and SMAD2, at both mRNA and protein levels (Figures 4B
and 4C), phosphorylation of SMAD2 (Figure 4C), and increased
secretion of TGF-b2 (Figure S4A). To test whether cytokine-induced
miR-148b downregulation governs EndMT, we analyzed endothelial-
and fibroblast-specific markers after the treatment with TNF-a/
IL-1b. Consistent with enhancement of EndMT, both mRNA and
protein expression of the endothelial markers CD31 and VE-cadherin
were decreased (Figures 4B and 4C). These findings were further
Figure 4. Chronic Inflammation Downregulates
miR-148b in ECs
HUVECs were treated with a combination of TNF-a and
IL-1b for 6 days. (A)miR-148b expression levels after TNF-
a/IL-1b treatment. (B) Relative expression of miR-148b,
TGFB2, SMAD2, CD31, VE-cadherin, SNAIL, SLUG,
TWIST, ZEB1/2, VIM, FSP-1, a-SMA, and COL1A1. (C)
Western blot analysis of TGFB2, p-SMAD2, SMAD2,
CD31, VE-cadherin, SLUG, FSP-1, and COL1A1; b-actin
was used as a loading control. (D) Immunofluorescence
images showing localization of CD31, VE-cadherin,
COL1A1, and FSP-1 in TNF-a/IL-1b-treated cells; scale
bars, 50 mm (magnification 400). Values are means ±
SEM. *p < 0.05; **p < 0.01 versus vehicle. Unpaired two-
tailed Student’s t test was applied.
www.moleculartherapy.org
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TNF-a/IL-1b (Figure 4D). In contrast, mRNA expression and protein
levels of fibroblast-specific COL1A1 and FSP-1 (Figures 4B and 4C)
were increased 6 days after TNF-a/IL-1b treatment, corroborated
by an increase in cellular and extracellular immunofluorescence sig-
nals (Figure 4D). Moreover, upregulation of SLUG was confirmed
at mRNA and protein levels in cytokine-treated ECs (Figures 4B
and 4C). Notably, HUVECs cultured for 14 days in the presence of
TNF-a/IL-1b maintained the downregulation of miR-148b and ac-
quired expression of a-SMA, in addition to other markers of EndMT
(Figures S5A and S5B).
Finally, we analyzed the expression of let-7b and miR-20a, miRNAs
involved in the EndMT process.31,32 While miR-20a and let-7b
were both downregulated in vivo during wound healing (Figure S6A),
only miR-20a was downregulated by cytokine treatment in ECs
(Figure S6B).
miR-148b Overexpression Rescues Cytokine-Mediated EndMT
We next examined whether miR-148b gain of function could rescue
the endothelial phenotype and reduce cytokine-induced EndMT. In
response to a miR-148b mimic, we observed a decreased in TGFB2,
SMAD2, SLUG, FSP-1, COL1A1, and a reduced phosphorylation of
SMAD2 in HUVECs treated with TNF-a/IL-1b, whereas expression
of CD31 and VE-cadherin at mRNA and protein levels was rescuedM(Figures S4B, S7A, and 5A). The maintenance
of endothelial markers CD31 and VE-cadherin
on EC membrane and the decrease of
COL1A1 and FSP-1 staining was also confirmed
by immunostaining (Figure 5B).
To better understand the contribution of target
genes in this model of EndMT, we interfered
with the TGF-b pathway using a TGF-b re-
ceptor (ALK5) inhibitor (SB431542) or small
interfering RNA (siRNA) for SMAD2. Knock-
down of SMAD2 in HUVECs treated with cy-tokines partially restored CD31 and VE-cadherin expression,
whereas blocking of ALK5 reduced the level of SMAD2 phosphor-
ylation but did not rescue endothelial marker expression (Figures
S7B and S7C). We next confirmed at protein level that the
SMAD2 siRNA partially restores the level of CD31 and VE-cadherin
in cytokine-treated ECs, whereas decreased SLUG, FSP-1, and
COL1A1 (Figure 5C). Changes in expression of CD31 and VE-cad-
herin, FSP-1, and COL1A1 were further confirmed by immunocyto-
chemistry (Figure 5D).
miR-148b Loss of Function Attenuates Wound Repair by
Enabling EndMT in a Skin-Wound-Healing Model
Next, we investigated whether miR-148b-mediated EndMT also oc-
curs in vivo in the mouse model of skin wound healing. Delivery
of anti-miR-148b or control oligonucleotides immediately after
wounding and every 2 days thereafter resulted in increased
mRNA expression of TGFB2 and SMAD2 targets in the wounds
(Figure S8A). Macroscopic analysis showed that wound closure
was markedly attenuated in anti-miR-148b-treated wounds (Fig-
ure 6A) without influencing wound perfusion and vessel density
(Figures S7C and S7D). There was not a significant improvement
in wound closure detected following SMAD2 siRNA only (Figures
6A and S8B). Next, to investigate EndMT at the wound
edge, wounds were stained with CD31 and FSP-1 and SLUG
antibodies (Figures 6B and 6C). Confocal analysis showed that whileolecular Therapy Vol. 26 No 8 August 2018 5
Figure 5. Overexpression of miR-148b Rescues
Cytokine-Induced EndMT
HUVECs were transfected with miR-148b mimic, SMAD2
siRNA, or control and treated with TNF-a/IL-1b for 6 days.
(A) Representative western blot analysis of TGFB2,
SMAD2, p-SMAD2 CD31, VE-cadherin, SLUG, FSP-1,
and COL1A1; HDAC3 is used as a loading control (n = 3).
(B) Immunofluorescence images showing localization of
CD31, VE-cadherin, COL1A1, and FSP-1 in miR-148b-
or control-transfected HUVECS and/or treated with TNF-
a/IL-1b; scale bars, 50 mm (magnification 400) (n = 3).
(C) Representative western blot analysis of SMAD2,
CD31, VE-cadherin, SLUG, COL1A1, and FSP-1;
HDAC3 is used as a loading control (n = 3). (D) Immu-
nofluorescence images showing localization of CD31,
VE-cadherin, COL1A1, and FSP-1 in SMAD2 siRNA or
control-transfected HUVECS and/or treated with TNF-
a/IL-1b; scale bars, 50 mm (magnification 400) (n = 3).
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Mesenchymal Transition during Skin Wound Healing, Molecular Therapy (2018), https://doi.org/10.1016/j.ymthe.2018.05.002control-oligonucleotide-treated wounds contained only CD31-posi-
tive vessels, anti-miR-148b-treated wounds were comprised of
CD31-FSP-1 or CD31-SLUG double-positive vessels, consistent
with the occurrence of EndMT (Figure 6D). Moreover, anti-miR-
148b-treated wounds showed an increase in the total number of
FSP-1-positive cells compared with the control oligonucleotide-
treated wounds (Figure 6D), whereas staining with PicroSirius
Red did not detect any increase of collagen deposition in the
wounds (Figure S8E). Finally, to confirm that loss of miR-148b-
mediated EndMT occurs through SMAD2 regulation, we knocked
down SMAD2 by siRNA in vivo in the anti-miR-148b-treated
wounds (Figure S8B). Knocking down SMAD2 in this model pro-
motes wound closure (Figure 6A) without significantly promoting
wound perfusion and vessel density (Figures S8C and S8D). More-
over, SMAD2 siRNA reduced the percentage of vessels double pos-
itive for CD31-FSP-1 and CD31-SLUG and decreased the total
number of FSP-1-positive cells in the wounds treated with anti-
miR-148b (Figure 6D). Overall, these results show that inhibition
of miR-148b in vivo impaired wound healing and promoted EndMT
on the wound edge via SMAD2.6 Molecular Therapy Vol. 26 No 8 August 2018DISCUSSION
We have comprehensively explored and been
able to demonstrate for the first time that
miR-148b has a crucial role in determining
EC function and plasticity by regulating the
TGF-b pathway. Overexpression of miR-
148b enhances EC proliferation, migration,
and in vitro angiogenesis via targeting
TGFB2 and SMAD2. In vivo delivery of
miR-148b to injured skin promotes angio-
genesis and accelerates wound closure. In
contrast, miR-148b inhibition promotes the
acquisition of a mesenchymal phenotype by
ECs by unlocking the expression of TGFB2
and SMAD2. This is associated with poorin vivo skin wound closure and activation of EndMT in dermal
vessels.
One of the first indications of the involvement of miRNAs in EndMT
came from Ghosh et al.,20 who reported differential expression of a
specific set of miRNAs during transition of mouse cardiac ECs to a
mesenchymal phenotype. Since then, miRNAs have been linked to
regulation of EndMT through different mechanisms. In vitro and
in vivo studies demonstrated that decreased fibroblast growth factor
(FGF) signaling leads to reduction in let-7 expression and initiation
of TGF-b-dependent Endo-MT.31 Recently, miR-20a was shown to
target multiple genes in TGF-b signaling, such as ALK5, TGF-bR2,
and SARA, thereby negatively regulating EndMT. The expression of
miR-20a, which is normally downregulated during EndMT, is rescued
by FGF2.32 In our study, both miR-20a and let-7b are downregulated
in vivo in the model of wound healing, whereas only miR-20a is also
downregulated by cytokine treatment in HUVECs. Interestingly,
further bioinformatic analysis demonstrated that the three miRNAs
target a different set of genes of the TGF-b pathway with minimal
(2 on 20 genes between miR-148b and let-7b) or no overlapping
Figure 6. Inhibition of miR-148b Delays Wound
Closure and Promotes EndMT in a Model of Wound
Healing
Dermal wounds were treated with anti-miR control or
siRNA control oligonucleotides and anti-miR-148b and/or
SMAD2 siRNA for 7 days. (A) Left, representative images
of treated wounds at 0 and 7 days post-wound-injury;
scale bar, 5 mm. Right, level of wound closure is ex-
pressed as a percentage of wound area from the initial
wound area (n = 8). (B) Immunohistochemical localization
of CD31 (green) and FSP-1 (red) in the wound vessels;
scale bars, 25 mm (magnification 630) (n = 8), nuclei are
stained with DAPI (blue). (C) Immunohistochemical
localization of CD31 and SLUG in wound vessels; scale
bars, 25 mm (magnification 630) (n = 8), nuclei are
stained with DAPI (blue). (D) Quantification of CD31/
FSP-1 double-positive vessels and FSP-1-positive cells
and CD31/SLUG double-positive vessels in the wounds;
n = 8 per each group. Values are expressed as means ±
SEM. *p < 0.05; **p < 0.01 versus anti-miR control.
#p < 0.05 versus anti-miR-148b. Unpaired two-tailed
Student’s t test and one-way ANOVA statistical test fol-
lowed by Bonferroni post-hoc analyses were applied.
www.moleculartherapy.org
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and miR-148b can interfere at different levels of the TGF-b pathway,
permitting a possible synergic effect during skin wound healing.
The occurrence of EndMT post-natally has been associated with
different types of fibrotic disease such as that in kidney12 and heart,11
both of which are associated with excessive collagen expression and
deposition. Previous studies reported the importance of EndMT in
dermal fibrosis, showing that delay in wound closure is associated
with excessive collagen deposition.33 In the present study, anti-
miR-148b-mediated EndMT have a detrimental influence on skin
wound closure, showing that around 30% of skin vessels are double
positive for CD31 and FSP-1. This is highly important because, so
transformed, these cells can be expected to secrete large amounts of
collagen and other ECM proteins, which could contribute to fibrosis.
In line with this, in our model we detected an increase in the recruit-Mment of FSP-1-positive cells in wound treated
with anti-miR-148b. However, analysis with
PicroSirius Red did not show any accumulation
of collagen in the wounds treated with anti-
miR-148b at day 7 after wounding.
EndMT may lead to ECs acquiring a variety of
different mesenchymal fates through different
stages of differentiation.4 The early endothelial
response is characterized by a partial downre-
gulation of endothelial markers, junction
dismantling, and upregulation of some early
mesenchymal markers. At later times, expres-
sion of endothelial markers further declineswhile more mesenchymal markers, including matrix proteins, are up-
regulated.4 An abnormally increased inflammatory environment is
often linked with phenotypic changes in ECs.34 Chronic treatment
of ECs with a combination of TNF-a and IL-1b over 6 days decreased
the expression of miR-148b in ECs while it increased the expression
and secretion of TGF-b2. In addition, the acquisition of a mesen-
chymal phenotype due to inflammation by dermal ECs is likely to
lead to endothelial dysfunction, seen through decreased ECmigration
or dysregulation of inflammatory cell recruitment.33
Inflammation is sufficient to induce all events required for EndMT
except for de novo acquisition of a-SMA, which is strictly dependent
on TGF-b 30. In our experiments, cytokine treatment or miR-148b in-
hibition increases the release of TGF-b2, as a direct target, which
drives the EndMT process, perhaps partly or incompletely at least af-
ter 6 days. Consequently, EndMT appeared complete after 14 days ofolecular Therapy Vol. 26 No 8 August 2018 7
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addition to other markers of EndMT.
Recent reports show that inflammatory cytokines such as TNF-a and
IL1-b can also trigger EndMT via binding to their receptors and by
inducing nuclear factor kB (NF-kB) translocation to the nucleus,
driving the expression of EndMT-specific genes.30,35 Such inflamma-
tory signals facilitate EndMT by increasing endogenous TGF-b
expression in an NFkB-dependent manner, creating a feed-forward
signaling mechanism.36 Interestingly, treatment with the miR-148b
mimics inhibited EndMT progression in cytokine-treated ECs. In
agreement with this, a recent study demonstrated that pro-inflamma-
tory molecules present in the serum of patients with Kawasaki syn-
drome induce EndMT through downregulation of miR-483 in ECs,
whereas the overexpression of miR-483 using mimic oligonucleotides
suppresses EndMT and restores EC function.37
In our in vitro model, the mechanism is based on activation of
SMAD2, as demonstrated by rescue of EndMT using SMAD2 anti-
sense. Alternatively, we have used SB43152, a specific inhibitor of
ALK5, at the dose of 10 mM to inhibit SMAD2 phosphorylation
and inhibit EndMT progression. However, SB43152 did not restore
endothelial markers in the same manner as miR-148b mimics and
SMAD2 siRNA. Discrepancy in outcomes is likely to be explained
by an action of the miR-148b mimic or SMAD2 siRNA through
SMAD2 mRNA degradation. In addition, another possible explana-
tion of lack of activity of the inhibitor of ALK5 is that SMAD2 could
be phosphorylated independently of ALK5 signaling by the mitotic
kinase Mps1.38
In the in vivo model of wound healing, SMAD2 siRNA rescued anti-
miR-148b-mediated EndMT and increased wound closure rate at day
7. However, at the same time point SMAD2 siRNA alone had no effect
on wound closure rate. The discrepancy of these results could be ex-
plained by a role for other SMAD-independent pathways during
wound closure and EndMT. For example, TGF-b and inflammatory
cytokines have been shown to activate diverse non-SMAD parallel
downstream pathways, such as extra-cellular signal-regulated kinase
(ERK), c-Jun NH2-terminal kinase (JNK), p38 mitogen-activated
protein (MAP) kinase.39 Moreover, a recent study that analyzed the
impact of EndMT on the skin wounds showed the existence of
Notch-mediated EndMT during skin wound healing.40
The participation of EndMT during wound healing merits further
confirmation and validation in future studies from individuals with
recognized clinical pathological conditions, such as diabetic non-
healing wounds. Such confirmation should lead to a change in the
paradigm of the origin of cells involved in the fibrotic process.
Furthermore, identification of the source of TGF-b and other active
ligands that can initiate EndMT and increased understanding of the
molecular mechanisms that regulate EndMT will be of great value
in providing cellular targets amenable to therapeutic intervention
for fibrotic disease. In our experience, the skin-wound-healing model
is an excellent model to assess the potential impact of EndMT on the8 Molecular Therapy Vol. 26 No 8 August 2018vessels that have formed during the wound-healing process. The exci-
sional wounds rapidly close, with the active tissue remodelling of the
wound area occurring in a reproducible way at specific time points.
The use of an endothelial lineage-tracing mouse model during wound
healing40 has recently further corroborated our data and highlighted
the critical role of EndMT during skin wound healing.
The TGF-b signaling pathway is considered a promising target for the
treatment of many diseases, including pathological skin conditions.
Most of the components of the TGF-b pathway have been targeted
for drug development through various strategies. Several, such as
oligonucleotide antisense, have been developed through pre-clinical
to clinical trials.41 Indeed, TGF-b antisense oligonucleotides reduced
scarring and improved surgical outcome in animal models.42 More-
over, Smad3 antisense oligonucleotides accelerated wound healing
and reduced scarring in a mouse excisional wound model.43 In this
context, the benefit of miRNA-based therapy is the possibility of
interfering with the regulation of multiple genes. Several miRNAs
have already been used as therapeutic tools in vascular disease17,18
to regulate different steps of the skin-wound-healing process.44
Considering this, we have demonstrated that miR-148b mimics
impact on different components of TGF-b pathway, thus amplifying
its therapeutic potential in a model of skin wound healing.
An important factor that we have considered in our in vivo experi-
ments is also at which stage of the wound-healing process treatment
with miR-148b mimics could be beneficial. Several studies have pre-
viously reported that reducing TGF-b pathway at later stages during
skin wound healing improved scarring outcome.45 Based on these ob-
servations, skin wounds in the present study were treated from 3 days
after wounding, when expression of miR-148b decreased, thus avoid-
ing early inhibition of TGF-b signaling during the inflammatory
phase, when it is required to start the healing process.46
In summary, the data presented here identify miR-148b as a novel
regulator of TGF-b signaling and EC plasticity and a potential thera-
peutic target for promotion of tissue repair.
MATERIALS AND METHODS
Cells and Cell Culture
HUVECs (Lonza) were grown in endothelial growth medium-2
(EGM-2) (comprising endothelial basal medium-2 [EBM-2] with
growth factors and other supplements) with 2% fetal bovine serum
(FBS). Confluent HUVECs were treated with 10 ng/mL TNF-a,
IL-1b, and TGF-b2 (PeproTech); medium and cytokines were
changed every 2 days. SB431542 (Tocris) has been used at the dose
of 10 mM. HEK293T cells (ATCC, CRL-11268) were cultured in
DMEM with 10% FBS (Life Technologies).
miR-148b Target Analysis
Computational prediction of miR-148b target genes was done using
published algorithm TargetScan (http://www.targetscan.org). miR-
path v.3 (http://diana.imis.athena-innovation.gr/DianaTools/index.
php?r=mirpath) was used to perform gene set enriched analysis of
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eters such as Context score and Conservation score. The Context
score for a specific site is the sum of the contribution of 14 features
of the 30 UTR structure;47 the Conservation score is the probability
of conserved targeting.48 TargetScan considers matches to human
30 UTRs and their orthologs, as defined by UCSC whole-genome
alignments. Lowest Context score shows a more favorable binding.
Higher conservation score represents a broad conservation of the
binding sites between the species.
RNA Extraction and Quantitative Real-Time Analysis
Total RNA was extracted using an miReasy kit (QIAGEN). Real-time
quantification to measure miRNA was performed with the TaqMan
miRNA reverse transcription kit and miRNA assay (Life Technolo-
gies) using Lightcycler 480 (Roche). miRNA expression was normal-
ized to the U6 small nucleolar RNA (snRU6). For mRNA analysis,
cDNA was amplified by quantitative real-time PCR (real-time
qPCR) and normalized to 18S ribosomal RNA. Each reaction was per-
formed in triplicate. Quantification was performed by the 2DDCt
method.49 Real-time qPCR was used to measure the expression of
miR-148b (miR-148b-3p Thermo Fisher Scientific, cat. #4426961),
snRU6 (Thermo Fisher Scientific, cat. #4331182), TGF-b2, SMAD2,
CD31, VE-cadherin, COL1A1, a-SMA, SLUG, VIM, SNAIL, TWIST,
ZEB1/2, and 18S rRNA. Pre-optimized primers were obtained from
Sigma (KiCqStart Primers).
Cell Transfection, Transduction, and Functional Assays
Lipofectamine RNAiMAX (Thermo Fisher Scientific) was used to
transfect HUVECs with miR-148b mimic, anti-miR-148b, and mimic
or anti-miR control (25 nM and 75 mM, respectively, final concentra-
tion) or with siRNA targeting SMAD2 (20 nM final concentration),
according to the manufacturer’s instructions. jetPEI-HUVECs (Poly-
plus) was used to transfect HUVECs with DNA plasmids. The
following functional assays were performed: BrdU incorporation
assay using Cell Proliferation colorimetric assay (Roche); Matrigel
assay with HUVECs was performed as previously described using
BD Matrigel Basement Membrane Matrix (BD Biosciences).50
ECIS Assays: Migration Assay and Plasma Membrane
Capacitance Analysis
Confluent HUVECs were transfected with controls or miR-148b
mimic or anti-miR-148b and plated on the electric cell-substrate
impedance sensing (ECIS) chip array (8W1E or 8W10E). The migra-
tion speed was calculated in mm/hr, capacitance of the plasma mem-
brane is capacitance (mF/cm2) as reported in Giaever and Keese.29
Western Blot Analyses
Proteins were extracted from cultured cells or muscles by using ice-
cold buffer A (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 25 mM sodium fluoride [NaF], 5 mM sodium pyrophosphate
[Na4P2O7], 1% Triton, 1% NP40, 1 mM sodium orthovanadate
[Na3VO4], 0.25% sodium deoxycholate, 0.5 mM Na-orthovanadate,
1 mM benzamidine, 0.1 mM phenylmethylsulfonyl fluoride). Protein
concentration was determined using the Bio-Rad Protein AssayReagent (Bio-Rad, UK). Detection of proteins by western blot ana-
lyses was done following separation of whole-cell extracts (20 mg)
on SDS-polyacrylamide gels. Proteins were transferred to nitrocellu-
lose membranes and probed with the following antibodies: TGF-b2
(Abcam, ab36495; 1:1,000), SMAD2 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, #3102, 1:1,000), p-SMAD2 (465/467) (Cell
Signaling, #3108; 1:1,000); CD31 (Abcam, 1:1,000), VE-cadherin (Ab-
cam, ab33168; 1:1,000), COL1A1 (Abcam, ab138492; 1:200), FSP-1
(S100A4; Abcam, ab41532; 1:1,000), SLUG (Abcam, ab27568;
1:1000), b-actin (Abcam, ab16039; 1:4,000), HDAC3 (GeneTex
GTX113303; 1:1,000), and GAPDH (GeneTex, GT239; 1:1,000)
(both used as loading control). For detection, we used secondary an-
tibodies conjugated to horseradish peroxidase, which were rabbit
anti-mouse (Abcam, ab97046; 1:5,000) and goat anti-rabbit (Abcam,
ab6721; 1:10,000). Detection was developed by enhanced chemilumi-
nescence reaction (ECL) (Immunoblot, Millipore, 23225).
Immunofluorescence
Cells were fixed using 4% paraformaldehyde in PBS at room tem-
perature for 15 min. For intracellular staining, fixed cells were per-
meabilized using 0.5% Triton X-100 in PBS (Sigma-Aldrich) or
0.1% Saponin in PBS at room temperature for 10 min. The block-
ing of specific antibody activity was performed using 3% BSA in
PBS for 1 hr. Samples were incubated with antibodies to CD31
(Abcam, ab28364; 1:50), VE-cadherin (Abcam, ab33168; 1:100),
FSP-1 (Abcam, ab41532; 1:200) and COL1A1 (Abcam, ab138492;
1:100) in PBS containing 1% BSA at 4C overnight. Samples
were washed extensively with PBS and incubated with Alexa Fluor
488-conjugated antibodies to rabbit immunoglobulin G (IgG) (Life
Technologies, Carlsbad, CA, #A11070) and Alexa Fluor 594-conju-
gated antibodies to rabbit IgG (Life Technologies, Carlsbad, CA,
#A11072) in DAPI with PBS with 1% BSA at room temperature
for 1 hr. Image analysis was performed on Zeiss LSM 780 confocal
microscope.
Luciferase Assay
Luciferase assay has been performed as previously described.50
TGFB2 30 UTR and SMAD2 30 UTR vectors were cloned in pMIR-
Reporter (Life Technologies). Primers are used for the cloning are
as follows: TGF-b2 30 UTR, forward 50-ATAAAGCTTATTTGCCA
CATCATTGCAGA-30, reverse 50-ATAACTAGTGGGAATAAAAA
GACGGCACA-30; SMAD2 30 UTR, forward 50-ATAAAGCTTT
GATCCAGCTAAGGTAACTGATGTT-30; reverse 50-ATAACTAG
TTGGTAAACAACTCAAATGGCTTTC-30. Primers for 30 UTR
mutation are as follows: TGFB2, forward 50-ATAAAGCTTATTTG
CCACATCATTGCAGA-30 and reverse 50-ATAACTAGTCCTATC
TGAGAGGAAAATGTCTGC-30; SMAD2, forward 50-ATAAAGC
TTTGATCCAGCTAAGGTAACTGATGTT-30 and reverse 50-ATA
ACTAGTGGACTTCCAGAGGGAAACAA-30. Luciferase constructs
were transfected into HEK293T cells or HUVECs together with
miR-148b mimics or p-SV-b-gal control vector. Cells were cultured
for 48 hr and assayed with the Luciferase and b-Galactosidase Re-
porter Assay Systems (Promega). Luciferase values were normalized
to protein concentration and b-galactosidase activity.Molecular Therapy Vol. 26 No 8 August 2018 9
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All experiments involving mice were performed in accordance with
the guidance and the operation of Animals (Scientific Procedures)
Act 1986 and prior approval of the UK Home Office and the Univer-
sity of Edinburgh Animal Welfare and Ethical Review Board. The
skin-wound-healing protocol was performed as described previ-
ously.51–53 CD-1 female mice (7 to 9 weeks old) (n = 8 per group)
were randomly assigned to a treatment group and anaesthetized
with isofluorane. Two full-thickness excisional wounds were made
to the shaved dorsal skin. Full-thickness excisional wounds were
made in a midline skin fold using a sterile, disposable 5-mm biopsy
punch (Kai Industries), resulting in generation of one wound on
each side of the midline. Control oligonucleotides (scramble
sequence), miR-148b mimic, Cy3-labeled miR-148b mimic, or anti-
miR-148b or SMAD2 siRNA (1 mg/wound) were delivered topically
by pipette into the wound cavity (10 mL in a vehicle of 30% Pluronic
F-127 gel [that is, liquid at 4C but solidifies at body temperature];
Sigma-Aldrich). Mimics were initially delivered after 3 days, whereas
anti-miR and siRNAwere delivered immediately after wounding. The
treatment was repeated every second day for 7 days. Wounds were
photographed using an Olympus camera on days 0, 2, 4, 6, and 7 after
wounding. Wound areas were calculated as previously described.51,52
In brief, wound diameter was measured using a Vernier caliper, and
wound area was calculated using a standard formula for the area of an
ellipse (semi-major diameter  semi-minor diameter  Pi). The su-
perficial blood flow of the wounds was sequentially analyzed by color
laser Doppler (Color Laser Doppler, Moor, UK), and the ratio of
blood flow between the mimic or anti-miR or siRNA-treated and
the control-treated wounds was calculated. Wound size and Doppler
analysis were performed in blinded fashion.
Histology and Image Analysis
Wounds were harvested, prepared, and analyzed as previously
described.51–53 At days 5 or 7 post-wounding, wounds were harvested
and fixed in 10% buffered formalin (16 hr at 4C, Sigma) for embed-
ding in paraffin. Sections were deparaffinized, rehydrated, and stained
with rat anti-mouse polyclonal CD31 (Abcam, ab28364; 1:50),
a-SMA (Sigma, A2547; 1:100), rabbit anti-mouse FSP-1 (Abcam,
ab41532; 1:50), and SLUG (Abcam, ab28364; 1:200); all antibodies
were used overnight at 4C. Stained slides were photographed and
analyzed in a blinded fashion using a Zeiss LSM 780 Confocal Micro-
scope (Zeiss). Vascular density in wounds was counted after immu-
nostaining for CD31 and a-SMA. Ten fields per section/animal
(n = 8 animal; 400 magnification) were randomly examined and
averaged to analyze the number of CD31-positive blood vessels in
the wound edges. Image analysis was performed using ImageJ soft-
ware as previously reported.51 Vascular density is expressed per
square millimeter. EndMT of ECs was assessed by FSP-1 and SLUG
immunostaining combined with CD31 staining. CD31-FSP-1 and
CD31-SLUG double-positive vessels are expressed as percentage of
positive vessels. For analysis of fibrosis, slides were stained with
PicroSirius Red (PSR) then photographed and analyzed in a blinded
fashion using a light microscope (Axioscope 2; Zeiss). Six images
per slide were captured at 400 magnification for PSR histological10 Molecular Therapy Vol. 26 No 8 August 2018staining. Color deconvolution in ImageJ software was used to evaluate
the percentage of red staining, which indicates the presence of
collagen fibers in the tissue. The area of collagen was measured as
the percentage of total pixels in each image, using the Threshold op-
tion in ImageJ software.
Statistical Analysis
Comparisons between two different conditions were assessed using
two-tailed Student’s t test. Differences among groups of more than
two were tested using one-way ANOVA, followed by Bonferroni
post-hoc analyses as appropriate. Data are expressed as mean ±
SEM of three independent experiments, each performed in triplicate
or quintuplicate, as reported in the figure legends. A p value < 0.05
was considered statistically significant. Analyses were performed
using GraphPad Prism v5.0.
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